WO2022023795A1 - Nutraceutical flour - Google Patents

Nutraceutical flour Download PDF

Info

Publication number
WO2022023795A1
WO2022023795A1 PCT/IB2020/057209 IB2020057209W WO2022023795A1 WO 2022023795 A1 WO2022023795 A1 WO 2022023795A1 IB 2020057209 W IB2020057209 W IB 2020057209W WO 2022023795 A1 WO2022023795 A1 WO 2022023795A1
Authority
WO
WIPO (PCT)
Prior art keywords
extracts
content
ground product
per
nutraceutical
Prior art date
Application number
PCT/IB2020/057209
Other languages
French (fr)
Inventor
Guglielmo Buonamici
Original Assignee
Food For Future S.R.L. Società Benefit
La Goccia S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Food For Future S.R.L. Società Benefit, La Goccia S.R.L. filed Critical Food For Future S.R.L. Società Benefit
Priority to PCT/IB2020/057209 priority Critical patent/WO2022023795A1/en
Publication of WO2022023795A1 publication Critical patent/WO2022023795A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • A23L19/12—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops of potatoes
    • A23L19/15—Unshaped dry products, e.g. powders, flakes, granules or agglomerates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the object of the present invention is a nutraceutical flour of the type outlined in the preamble of claim 1.
  • flours As it is known, flours, durum wheat flours, coarse durum wheat flours (hereinafter simply and univocally called flours) obtained by grinding dried fruits or seed are nowadays marketed.
  • the most commercially used flour is the type 0 soft wheat flour having a maximum ash content of 0.65 e minimum protein content equal to 11.00 and, mainly, type 00 soft wheat flours characterized by a maximum ash content of 0.55 and a minimum protein content equal to 9.
  • These flours are obtained by industrially grinding wheat grains which causes the removal of the germ (the nutritive core of the grain containing amino acids, fatty acids, B vitamins, vitamin E) and bran (the grain outermost part rich of fibers).
  • the human body is subjected to greater fat deposits and to a fast increase of weight and of the content of triglycerides and low-density apolipoproteins, for example.
  • Such condition can cause cardiocirculatory diseases and metabolic disorders.
  • the technical task underlying the present invention consists of devising a nutraceutical flour capable of substantially overcome at least part of the cited drawbacks.
  • an important object of the invention is to provide a nutraceutical flour characterized by an improvement of the nutritional properties and therefore uncapable of causing greater fat deposit, fast weight increase, an overload on one or more organs or other issues tied to the intake of the known flours.
  • the technical task and the specified objects are met by a nutraceutical flour as claimed in the attached claim 1 . Examples of preferred embodiments are described in the dependent claims.
  • measurements, values, shapes, and geometrical references when associated to words like “about” or other similar terms such “almost” or “substantially” should be meant without measurement errors or other inaccuracies determined by production and/or manufacturing errors and, mainly, without a slight difference from the value of the measurement, from the shape or geometrical reference which is associated to. For example, such terms if are associated to a value, indicate a difference not greater than 10% than the same value.
  • first”, “second”, “upper”, “lower”, “main”, and “secondary, when used, do not necessarily mean a sequence, a priority of a relationship or relative position, but can be simply used for more clearly distinguishing different components from each other.
  • the nutraceutical flour can comprise a ground product.
  • the ground product can be obtained by grinding one or more, for example, of dried fruits and plant seeds such as for example, corn, barley, emmer wheat, rice, oat, rye, chestnuts, chickpeas, almonds, and buckwheat.
  • the ground product is obtained by grinding soft wheat. It can be one of known products such as: type 00, 0, 1 , 2, soft wheat flour or whole wheat flour.
  • the nutraceutical flour can comprise extracts of Saccharum officinarum, suitably obtained from stalk of Saccharum officinarum.
  • the extracts of Saccharum officinarum can comprise policosanols, and more particularly octacosanols.
  • Saccharum officinarum extracts can comprise one or more and particularly all vitamins B and/or E.
  • the content of Saccharum officinarum extracts can be substantially less than 3.0 g, in particular less than 1.0 g, and more particularly substantially comprised between 0.75 g and 0.25 per kg of the ground product. Preferably, it is substantially comprised between 0.4 g and 0.5 g per kg of the ground product.
  • the nutraceutical flour can comprise extracts of Medicago sativa L, in the following simply called Medicago sativa, suitably obtained by leaves of Medicago sativa.
  • the extracts of Medicago sativa can comprise triterpenic saponins and folic acid suitably in the 5-methyl-tetrahydrofolate form.
  • the Medicago sativa extracts can comprise one or more and particularly all the isoflavones, policosanols, and coumarins.
  • the content of Medicago sativa extracts can be substantially less than 10.0 g, particularly less than 5.0 g, and more particularly substantially comprised between 0.5 and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1.0 g per kg of the ground product.
  • the content of Medicago sativa extracts can be substantially greater than the one of the Saccharum officinarum extracts.
  • the nutraceutical flour can comprise extracts of Cyclanthera pedata suitably obtained from the Cyclanthera pedata fruits.
  • the Cyclanthera pedata extracts can comprise phytosterols and particularly sitosterol-3-p-D-glycoside.
  • the content of Cyclanthera pedata extracts can be substantially less than 10.0 g, particularly less than 5.0 g, and more particularly substantially less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1 g per kg of the ground product.
  • Cyclanthera pedata extracts can be substantially equal to the one of the Medicago sativa extracts. Alternatively, it can be substantially less than the one of the Saccharum officinarum extracts.
  • the nutraceutical flour can comprise extracts of Silybum marianum suitably obtained from fruits of Silybum marianum.
  • the Silybum marianum extracts can comprise silymarin.
  • the content of Silybum marianum extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 0.5 g and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1.0 g per kg of the ground product.
  • the content of Silybum marianum extracts can be substantially equal to the one of the Medicago sativa extracts.
  • the nutraceutical flour can comprise extracts of Berberis vulgaris L. in the following simply called Berberis vulgaris, suitably obtained by roots of Berberis vulgaris.
  • the Berberis vulgaris extracts can contain berberine.
  • the Berberis vulgaris extracts can comprise one or more and, particularly, all of oxyacanthine, berbamine, palmatine, berberrubine, ijatrorrhizine, columbamine (alkaloids), tannin, pectin, citric acid, malic acid, tartaric acid.
  • the content of Berberis vulgaris extracts can be substantially less than 10.0 g, particularly less than 5.0 g, and more particularly substantially comprised between 1 .0 g e 3.0 g per kg of the ground product. Preferably, it is substantially equal to 1.5 g per kg of the ground product.
  • the content of Berberis vulgaris extracts can be substantially greater than the one of the Medicago sativa.
  • the nutraceutical flour can comprise extracts of Lentinula erode (Berk.) Pegler, in the following simply called Lentinula erode, suitably obtained by the whole Lentinula erode.
  • the Lentinula erode extracts can comprise b-glucans.
  • the Lentinula erode extracts can comprise one or more and in particular all of essential amino acids, minerals such as potassium, calcium, zinc, B vitamins (thiamine, riboflavin, niacin), ergosterol, lentinan polysaccharide, eritadenine, and lanthionine.
  • the content of Lentinula erode extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 1.0 g and 3.0 g per kg of the ground product. Preferably, it is substantially equal to 1.5 g per kg of ground product.
  • the content of Lentinula erode extracts can be substantially greater than the one of the Medicago sativa extracts, and suitably almost equal to the ones of the Berberis vulgaris extracts.
  • the nutraceutical flour can comprise extracts of Avena sativa L, in the following simply called Avena sativa, suitably obtained from suitably soluble fiber of Avena sativa.
  • the Avena sativa extracts can comprise b-glucans.
  • the Avena sativa extracts can comprise one or more, and particularly all the carbohydrates, starch, proteins, unsaturated fats, mineral salts, vitamins B, C, E, and avenin.
  • the content of Avena sativa extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 1 .0 and 3.0 g per kg of the ground product. Preferably, it is substantially equal to 2.0 per kg of the ground product.
  • the content of Avena sativa extracts can be substantially greater than the one of the Saccharum officinarum extracts and particularly of Medicago sativa extracts.
  • the nutraceutical flour can comprise extracts of Hordeum vulgare, particularly the waxy variety, simply called in the following Hordeum vulgare, suitably obtained from Hordeum vulgare caryopsis.
  • the Hordeum vulgare extracts can comprise b-glucans.
  • Hordeum vulgare extracts can comprise one or more and particular all the soluble polysaccharides.
  • the content of Hordeum vulgare extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 1.0 g and 3.0 g per kg of the ground product. Preferably, it is substantially equal to 2 g per kg of the ground product.
  • the content of Hordeum vulgare extracts can be substantially greater than the one of the Saccharum officinarum extracts and particularly of the Medicago sativa extracts. Said content can be almost equal to the one of the Avena sativa extracts.
  • the nutraceutical flour can comprise extracts of Saccharomyces cerevisiae, suitably obtained from fungi of Saccharomyces cerevisiae.
  • Saccharomyces cerevisiae extracts can comprise B vitamins and/or folic acid.
  • Saccharomyces cerevisiae extracts can comprise one or more and in particular all the proteins, mineral salts (particularly magnesium, potassium, phosphor, iron, calcium, and selenium), folic acid.
  • the content of Saccharomyces cerevisiae extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly comprised between 0.5 g and 2 g per kg of ground product. Preferably, it is substantially equal to 1 g per kg of the ground product.
  • the content of Saccharomyces cerevisiae extracts can be substantially equal to the one of the Medicago sativa extracts.
  • the nutraceutical flour can comprise extracts of Saccharomyces boulardii suitably obtained from fungi of Saccharomyces boulardii.
  • the Saccharomyces boulardii extracts can comprise B vitamins and/or folic acid.
  • Saccharomyces boulardii extracts can comprise one or more or in particular all the proteins, mineral salts (specifically magnesium, potassium, phosphor, iron, calcium, and selenium), folic acid.
  • mineral salts specifically magnesium, potassium, phosphor, iron, calcium, and selenium
  • the content of Saccharomyces boulardii extracts can be substantially less than 10.0 g, in particular less than 5 g, and more particularly substantially comprised between 0.5 g and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1 g per kg of the ground product.
  • Saccharomyces boulardii extracts can be substantially equal to the one of the Medicago sativa extracts and therefore of the Saccharomyces cerevisiae extracts.
  • the nutraceutical flour can comprise extracts of Ganoderma Lucidum (Reishi), in the following simply called Ganoderma Lucidum, suitable obtained from sporophores of Ganoderma Lucidum.
  • the extracts of Ganoderma Lucidum can comprise b-glucans and germanium.
  • the Ganoderma Lucidum extracts can comprise one or more and in particular all of the mineral salts (such as Fe-Zn-Cu-Mn-Mg-K-Ca and germanium), vitamins specifically A, C, E, and in particular B (especially folic acid), ergosterine, amino acids, enzymes, Ling Zhi 8 protein, sterols, adenosine, polisaccharides (consisting of glucose, galactose, mannose with parts of xylose and fucose) and triterpenes such as lucidenic acid and ganoderic acid.
  • the mineral salts such as Fe-Zn-Cu-Mn-Mg-K-Ca and germanium
  • vitamins specifically A, C, E, and in particular B especially folic acid
  • ergosterine amino acids
  • enzymes Ling Zhi 8 protein
  • sterols adenosine
  • polisaccharides consisting of glucose, galactose, mannose with parts of
  • the content of Ganoderma Lucidum extracts is substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 0.5 g and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1.0 g per kg of the ground product.
  • the content of Ganoderma Lucidum extracts is substantially equal to the one of the Medicago sativa.
  • the nutraceutical flour can comprise extracts of Vitis vinifera suitably obtained from skins of berries and/or shoots of Vitis vinifera.
  • the Vitis vinifera extracts can comprise resveratrol and pterostilbene.
  • the content of Vitis vinifera extracts can be substantially comprised between 1.0 g and 10.0 g, in particular between 2.0 g and 5.0 g, and more particularly between 2.5 g and 4.0 g per kg of the ground product. Preferably, it is substantially equal to 3.0 g per kg of the ground product.
  • Vitis vinifera extracts can be substantially greater than the one of the extracts of Saccharum officinarum, in particular of Medicago sativa and more particularly of Hordeum vulgare.
  • the nutraceutical flour can comprise extracts of Beta vulgaris suitably obtained from the root of Beta vulgaris.
  • Beta vulgaris extracts can comprise stachydrine, equivalent to proline and betaine (known as trimethylglycine).
  • Beta vulgaris extracts can be substantially less than 10.0 g. in particular less than 5.0 g, and more particularly less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1 .0 g per kg of the ground product.
  • Beta vulgaris extracts can be substantially equal to the one of the extracts of Saccharum officinarum. It is almost equal to the one of the Medicago sativa.
  • the nutraceutical flour can comprise extracts of Boletus edulis suitably obtained from the whole mushroom.
  • the Boletus edulis extracts can comprise trimethylglicine.
  • the Boletus edulis extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1 g per kg of the ground product.
  • the content of the Boletus edulis extracts can be substantially equal to the one of the Saccharum officinarum extracts. It is almost equal to the one of Medicago sativa and preferably of Beta vulgaris.
  • the nutraceutical flour comprises extracts of Beta vulgaris and Boletus edulis.
  • the nutraceutical flour can comprise extracts of Cynara scolymus L, in the following simply called Cynara scolymus, suitably obtained from leaves of Cynara scolymus.
  • the Cynara scolymus extracts can comprise cynarine obtained only by a drying process.
  • Cynara scolymus extracts can comprise one or more and in particular all the cynarine, polyphenols, polyacetyls, sterols, organic acids (such as 5-caffeoylquinic acid or chlorogenic acid), sesquiterpene lactones, cynaropicrin, and derivatives thereof, mineral salts, and volatile aromatic components.
  • the content of Cynara scolymus can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1.0 g per kg of the ground product.
  • the content of the Cynara scolymus can be substantially greater than the one of the Saccharum officinarum extracts. It is almost equal to the one of the Medicago sativa.
  • the nutraceutical flour can comprise extracts of Grifola frondosa suitably obtained from the carpophore of Grifola frondosa.
  • the extracts of Grifola frondosa can comprise b-glucans.
  • the content of Grifola frondosa extracts can be substantially less than 1.0 g, in particular less than 1 .0 g, more particularly less than 0.5 g, and still more particularly less than 0.1 g per kg of the ground product. Preferably, it is substantially equal to 0.05 g per kg of the ground product.
  • the content of the Grifola frondosa extracts can be substantially less than the one of the Saccharum officinarum extracts.
  • the nutraceutical flour can comprise extracts of Cordyceps sinensis suitably obtained from the mycelium of Cordyceps sinensis.
  • the Cordyceps sinensis extracts can comprise polysaccharides and b-glucans.
  • Cordyceps sinensis extracts can comprise one or more and particularly all of cordycepic acid, galactomannan, b-mannans.
  • the content of the Cordyceps sinensis extracts can be substantially less than 1 .0 g, in particular less than 0.5 g, and still more particularly less than 0.1 g per kg of the ground product. Preferably, it is substantially equal to 0.05 per kg of the ground product.
  • the content of the Cordyceps sinensis extracts can be substantially less than the one of the Saccharum officinarum extracts. It can be almost equal to the content of Grifola frondosa extracts.
  • the nutraceutical flour can substantially comprise a ground product and, for each kg of said ground product, from 0.4 to 0.5 g of Saccharum officinarum extracts, 1.0 g of Medicago sativa extracts, from 0.05 to 1 g of Cyclanthera pedata extracts, 1 .0 g of Silybum marianum extracts, 1.5 g of Lentinula erode extracts, 2.0 g of Avena sativa extracts, 2.0 g of Hordeum vulgare extracts, 1.0 g of Saccharomyces cerevisiae extracts, 1.0 g of Saccharomyces boulardii extracts, 1 .5 g of Berberis vulgaris extracts, 1 .0 g of Ganoderma Lucid urn extracts, 3.0 g of Vitis vinifera extracts, at least one of extracts of Beta vulgaris (content from 0.05 to 1.0 g), and Boletus ed
  • extracts can be obtained, preferably, by the Soxhlet-type reflux extraction, and in particular by ultrasounds or supercritical gases, and the addition, as solvent, of sulfur dioxide.
  • extracts are obtained by the Soxhlet methanol reflux method.
  • This method comprises: fermentation and hydrolysis of part of a plant (e.g. fruits, flowers, or leaves) from which the extracts are obtained by adding yeast suitably Saccharomycetaceae (e.g.
  • Saccharomyces cerevisiae Saccharomyces cerevisiae and preferably with a pH of 7 for about 4 days; evaporation and centrifuging of the extracts for eliminating the solvent from the obtained solution, Soxhlet extraction; elimination of the methanol by heating it to the boiling point thereof, and consequent extraction by evaporation.
  • Saccharum officinarum extracts can be obtained by a solvent-free cold pressing.
  • the invention comprises a new process for producing a nutraceutical flour.
  • the production process can comprise a grinding step by which the ground product is obtained, for example, by grinding one or more dried fruits or plant seeds (corn, barley, emmer wheat, rice, oat, rye, chestnuts, chickpeas, almonds, and buckwheat) and similar.
  • a grinding step by which the ground product is obtained, for example, by grinding one or more dried fruits or plant seeds (corn, barley, emmer wheat, rice, oat, rye, chestnuts, chickpeas, almonds, and buckwheat) and similar.
  • the production process can comprise a step of mixing one or more of said extracts with the ground product.
  • additional extracts of Saccharum officinarum can be suitably added to the ground product according to said contents.
  • additional extracts of Silybum marianum can be suitably added to the ground product according to said contents.
  • additional extracts of Avena sativa can be suitably added to the ground product in order to obtain said content.
  • additional extracts of Hordeum vulgare can be suitably added to the ground product according to said contents.
  • additional extracts of Beta vulgaris can be suitably added to the ground product according to said contents.
  • additional extracts of Cordyceps sinensis can be suitably added to the ground product according to said contents.
  • the production process can comprise a step of methylating at least part and in particular all the resveratrol in said extracts (suitably of Vitis vinifera) in pterostilbene.
  • the step of methylating folic acid (present at least in the Medicago sativa, Saccharomyces cerevisiae, and/or Saccharomyces boulardii) makes available at least part of the methyl groups present in a methyl group donor (e. g. trimethylglicine, contained in the Beta vulgaris and/or Boletus edulis extracts) which perform the step of methylating resveratrol for obtaining pterostilbene.
  • a methyl group donor e. g. trimethylglicine, contained in the Beta vulgaris and/or Boletus edulis extracts
  • trimethylglicine (N,N,N-trimethylglicine or preferably a N-trimethylated amino acid in the neutral pH zwitterionic form) perform a methylating action on the resveratrol causing the formation of pterostilbene.
  • the trimethylglicine action by folic acid, remethylates resveratrol by reducing also 5-methyl- tetrahydrofolate (MHTF) to methyl tetrahydrofolate, which provides the methyl group required to form, by resveratrol, pterostilbene.
  • MHTF 5-methyl- tetrahydrofolate
  • the nutraceutical flour according to the invention obtains important advantages. Indeed, the nutraceutical flour is effective at countering unbalances such as the ones regarding the cholesterol, immunitary and/or cardiovascular systems, hypoglycemia, due to the Vitis vinifera pterostilbene (suitably obtained by said methylation step) performing a hypocholesterolemizing, anti-inflammatory, antimicrobial, antiviral actions.
  • hypocholesterolemizing action is aided by folic acid and/or Saccharum officinarum extracts which, due to policasonols, vitamins E, and B, reduce the cholesterol, in particular the LDL type.
  • folic acid and/or Saccharum officinarum extracts which, due to policasonols, vitamins E, and B, reduce the cholesterol, in particular the LDL type.
  • Such action is augmented by the Medicago sativa extracts which, acting on the livery and detoxification systems augment the hypocholesterolemizing action of the Saccharum officinarum and Vitis vinifera extracts.
  • the inventor outlines the important functional contribution of the b-glucans (present in one or more of the Hordeum vulgare, Avena sativa, Lentinula erode, Cordyceps sinensis, Grifola frondosa, and/or Ganoderma Lucidum) capable of collecting and absorbing LDL cholesterol consequently contributing to the protection against cardiocirculatory diseases and strokes.
  • saccharase present in the Saccharomyces cerevisiae, Saccharomyces boulardii and/or Beta vulgaris
  • saccharase present in the Saccharomyces cerevisiae, Saccharomyces boulardii and/or Beta vulgaris
  • An important action of the b-glucans is also the reduction of the hormone ghrelin and consequently the reduction of the body weight and of the visceral fat mass. This action is enhanced by extracts of Medicago sativa (capable of controlling sugars in the blood, and hyperglycemia due to the contents of alkaloids, asparagine, and trigonelline), of Berberis vulgaris and Silybum marianum (capable of increasing the hypolipemic action of berberine) and/or of Avena sativa having a fat burning action.
  • the nutraceutical flour has strong action on the immunitary system given by the b- glucans.
  • nutraceutical flour Another advantage of the nutraceutical flour is its positive action on the cardiovascular system. Indeed, the policosanols of the Saccharum officinarum extracts have an anti-platelet action which consequently reduces blot clots and prevents the smooth muscle cells of the vessel wall from proliferating.
  • the nutraceutical flour is characterized in that it curbs and controls the hematic cholesterol levels, controls and reduces low density apolipoproteins, curbs and increases high density apolipoproteins, curbs and controls the hematic homocysteine, protects arteries and cardiocirculatory system and is characterized for its scavenging and hepatic steatosis countering actions.
  • the invention is susceptible to be implemented in variants falling in the scope of the inventive idea defined in the claims. In such scope, all the details can be substituted by equivalent elements and materials, sizes can be of any type.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A nutraceutical flour comprising a ground product and Saccharum officinarum, Medicago sativa, Cyclanthera pedata, Silybum marianum, Lentinula erode, Avena sativa, Hordeum vulgare, Saccharomyces cerevisiae, Saccharomyces boulardii, Berberis vulgaris, Ganoderma Lucidum, Vitis vinifera extracts and at least one of Beta vulgaris extracts and Boletus edulis extracts, is provided.

Description

DESCRIPTION
NUTRACEUTICAL FLOUR
The object of the present invention is a nutraceutical flour of the type outlined in the preamble of claim 1.
As it is known, flours, durum wheat flours, coarse durum wheat flours (hereinafter simply and univocally called flours) obtained by grinding dried fruits or seed are nowadays marketed.
Among said flours, the most commercially used flour is the type 0 soft wheat flour having a maximum ash content of 0.65 e minimum protein content equal to 11.00 and, mainly, type 00 soft wheat flours characterized by a maximum ash content of 0.55 and a minimum protein content equal to 9.
These flours are obtained by industrially grinding wheat grains which causes the removal of the germ (the nutritive core of the grain containing amino acids, fatty acids, B vitamins, vitamin E) and bran (the grain outermost part rich of fibers).
All this enables to obtain a refined flour characterized by a long shelf life, unfortunately this flour is heavily deficient of nutritional principles and has a very high content of sugars.
Therefore, almost all the products obtained from the known flours can cause a substantial increase of the blood sugar levels and consequently an increase of the glucose production.
Consequently, the human body is subjected to greater fat deposits and to a fast increase of weight and of the content of triglycerides and low-density apolipoproteins, for example.
Such condition can cause cardiocirculatory diseases and metabolic disorders.
In this condition, the technical task underlying the present invention consists of devising a nutraceutical flour capable of substantially overcome at least part of the cited drawbacks.
In the context of said technical task, an important object of the invention is to provide a nutraceutical flour characterized by an improvement of the nutritional properties and therefore uncapable of causing greater fat deposit, fast weight increase, an overload on one or more organs or other issues tied to the intake of the known flours. The technical task and the specified objects are met by a nutraceutical flour as claimed in the attached claim 1 . Examples of preferred embodiments are described in the dependent claims.
In the present document, measurements, values, shapes, and geometrical references (as perpendicularity and parallelism), when associated to words like “about” or other similar terms such “almost” or “substantially” should be meant without measurement errors or other inaccuracies determined by production and/or manufacturing errors and, mainly, without a slight difference from the value of the measurement, from the shape or geometrical reference which is associated to. For example, such terms if are associated to a value, indicate a difference not greater than 10% than the same value.
Moreover, terms such as “first”, “second”, “upper”, “lower”, “main”, and “secondary, when used, do not necessarily mean a sequence, a priority of a relationship or relative position, but can be simply used for more clearly distinguishing different components from each other.
Measurements and data given in the present document are considered, unless otherwise noted, as performed in the ICAO International Standard Atmosphere (ISO 2533).
The nutraceutical flour can comprise a ground product. The ground product can be obtained by grinding one or more, for example, of dried fruits and plant seeds such as for example, corn, barley, emmer wheat, rice, oat, rye, chestnuts, chickpeas, almonds, and buckwheat.
Preferably, the ground product is obtained by grinding soft wheat. It can be one of known products such as: type 00, 0, 1 , 2, soft wheat flour or whole wheat flour.
The nutraceutical flour can comprise extracts of Saccharum officinarum, suitably obtained from stalk of Saccharum officinarum.
The extracts of Saccharum officinarum can comprise policosanols, and more particularly octacosanols.
In addition, Saccharum officinarum extracts can comprise one or more and particularly all vitamins B and/or E.
The content of Saccharum officinarum extracts can be substantially less than 3.0 g, in particular less than 1.0 g, and more particularly substantially comprised between 0.75 g and 0.25 per kg of the ground product. Preferably, it is substantially comprised between 0.4 g and 0.5 g per kg of the ground product.
The nutraceutical flour can comprise extracts of Medicago sativa L, in the following simply called Medicago sativa, suitably obtained by leaves of Medicago sativa.
The extracts of Medicago sativa can comprise triterpenic saponins and folic acid suitably in the 5-methyl-tetrahydrofolate form.
In addition, the Medicago sativa extracts can comprise one or more and particularly all the isoflavones, policosanols, and coumarins.
The content of Medicago sativa extracts can be substantially less than 10.0 g, particularly less than 5.0 g, and more particularly substantially comprised between 0.5 and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1.0 g per kg of the ground product. The content of Medicago sativa extracts can be substantially greater than the one of the Saccharum officinarum extracts.
The nutraceutical flour can comprise extracts of Cyclanthera pedata suitably obtained from the Cyclanthera pedata fruits.
The Cyclanthera pedata extracts can comprise phytosterols and particularly sitosterol-3-p-D-glycoside.
The content of Cyclanthera pedata extracts can be substantially less than 10.0 g, particularly less than 5.0 g, and more particularly substantially less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1 g per kg of the ground product.
The content of Cyclanthera pedata extracts can be substantially equal to the one of the Medicago sativa extracts. Alternatively, it can be substantially less than the one of the Saccharum officinarum extracts.
The nutraceutical flour can comprise extracts of Silybum marianum suitably obtained from fruits of Silybum marianum.
The Silybum marianum extracts can comprise silymarin.
The content of Silybum marianum extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 0.5 g and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1.0 g per kg of the ground product.
The content of Silybum marianum extracts can be substantially equal to the one of the Medicago sativa extracts.
The nutraceutical flour can comprise extracts of Berberis vulgaris L. in the following simply called Berberis vulgaris, suitably obtained by roots of Berberis vulgaris.
The Berberis vulgaris extracts can contain berberine. In addition, the Berberis vulgaris extracts can comprise one or more and, particularly, all of oxyacanthine, berbamine, palmatine, berberrubine, ijatrorrhizine, columbamine (alkaloids), tannin, pectin, citric acid, malic acid, tartaric acid.
The content of Berberis vulgaris extracts can be substantially less than 10.0 g, particularly less than 5.0 g, and more particularly substantially comprised between 1 .0 g e 3.0 g per kg of the ground product. Preferably, it is substantially equal to 1.5 g per kg of the ground product.
The content of Berberis vulgaris extracts can be substantially greater than the one of the Medicago sativa.
The nutraceutical flour can comprise extracts of Lentinula erode (Berk.) Pegler, in the following simply called Lentinula erode, suitably obtained by the whole Lentinula erode.
The Lentinula erode extracts can comprise b-glucans.
The Lentinula erode extracts can comprise one or more and in particular all of essential amino acids, minerals such as potassium, calcium, zinc, B vitamins (thiamine, riboflavin, niacin), ergosterol, lentinan polysaccharide, eritadenine, and lanthionine.
The content of Lentinula erode extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 1.0 g and 3.0 g per kg of the ground product. Preferably, it is substantially equal to 1.5 g per kg of ground product.
The content of Lentinula erode extracts can be substantially greater than the one of the Medicago sativa extracts, and suitably almost equal to the ones of the Berberis vulgaris extracts.
The nutraceutical flour can comprise extracts of Avena sativa L, in the following simply called Avena sativa, suitably obtained from suitably soluble fiber of Avena sativa.
The Avena sativa extracts can comprise b-glucans.
In addition, the Avena sativa extracts can comprise one or more, and particularly all the carbohydrates, starch, proteins, unsaturated fats, mineral salts, vitamins B, C, E, and avenin.
The content of Avena sativa extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 1 .0 and 3.0 g per kg of the ground product. Preferably, it is substantially equal to 2.0 per kg of the ground product.
The content of Avena sativa extracts can be substantially greater than the one of the Saccharum officinarum extracts and particularly of Medicago sativa extracts. The nutraceutical flour can comprise extracts of Hordeum vulgare, particularly the waxy variety, simply called in the following Hordeum vulgare, suitably obtained from Hordeum vulgare caryopsis.
The Hordeum vulgare extracts can comprise b-glucans.
In addition, the Hordeum vulgare extracts can comprise one or more and particular all the soluble polysaccharides.
The content of Hordeum vulgare extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 1.0 g and 3.0 g per kg of the ground product. Preferably, it is substantially equal to 2 g per kg of the ground product.
The content of Hordeum vulgare extracts can be substantially greater than the one of the Saccharum officinarum extracts and particularly of the Medicago sativa extracts. Said content can be almost equal to the one of the Avena sativa extracts.
The nutraceutical flour can comprise extracts of Saccharomyces cerevisiae, suitably obtained from fungi of Saccharomyces cerevisiae.
The Saccharomyces cerevisiae extracts can comprise B vitamins and/or folic acid. In addition, Saccharomyces cerevisiae extracts can comprise one or more and in particular all the proteins, mineral salts (particularly magnesium, potassium, phosphor, iron, calcium, and selenium), folic acid.
The content of Saccharomyces cerevisiae extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly comprised between 0.5 g and 2 g per kg of ground product. Preferably, it is substantially equal to 1 g per kg of the ground product.
The content of Saccharomyces cerevisiae extracts can be substantially equal to the one of the Medicago sativa extracts.
The nutraceutical flour can comprise extracts of Saccharomyces boulardii suitably obtained from fungi of Saccharomyces boulardii.
The Saccharomyces boulardii extracts can comprise B vitamins and/or folic acid.
In addition, the Saccharomyces boulardii extracts can comprise one or more or in particular all the proteins, mineral salts (specifically magnesium, potassium, phosphor, iron, calcium, and selenium), folic acid.
The content of Saccharomyces boulardii extracts can be substantially less than 10.0 g, in particular less than 5 g, and more particularly substantially comprised between 0.5 g and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1 g per kg of the ground product.
The content of Saccharomyces boulardii extracts can be substantially equal to the one of the Medicago sativa extracts and therefore of the Saccharomyces cerevisiae extracts.
The nutraceutical flour can comprise extracts of Ganoderma Lucidum (Reishi), in the following simply called Ganoderma Lucidum, suitable obtained from sporophores of Ganoderma Lucidum.
The extracts of Ganoderma Lucidum can comprise b-glucans and germanium.
In addition, the Ganoderma Lucidum extracts can comprise one or more and in particular all of the mineral salts (such as Fe-Zn-Cu-Mn-Mg-K-Ca and germanium), vitamins specifically A, C, E, and in particular B (especially folic acid), ergosterine, amino acids, enzymes, Ling Zhi 8 protein, sterols, adenosine, polisaccharides (consisting of glucose, galactose, mannose with parts of xylose and fucose) and triterpenes such as lucidenic acid and ganoderic acid.
The content of Ganoderma Lucidum extracts is substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially comprised between 0.5 g and 2.0 g per kg of the ground product. Preferably, it is substantially equal to 1.0 g per kg of the ground product.
The content of Ganoderma Lucidum extracts is substantially equal to the one of the Medicago sativa.
The nutraceutical flour can comprise extracts of Vitis vinifera suitably obtained from skins of berries and/or shoots of Vitis vinifera.
The Vitis vinifera extracts can comprise resveratrol and pterostilbene.
The content of Vitis vinifera extracts can be substantially comprised between 1.0 g and 10.0 g, in particular between 2.0 g and 5.0 g, and more particularly between 2.5 g and 4.0 g per kg of the ground product. Preferably, it is substantially equal to 3.0 g per kg of the ground product.
The content of Vitis vinifera extracts can be substantially greater than the one of the extracts of Saccharum officinarum, in particular of Medicago sativa and more particularly of Hordeum vulgare.
The nutraceutical flour can comprise extracts of Beta vulgaris suitably obtained from the root of Beta vulgaris.
The Beta vulgaris extracts can comprise stachydrine, equivalent to proline and betaine (known as trimethylglycine).
The content of Beta vulgaris extracts can be substantially less than 10.0 g. in particular less than 5.0 g, and more particularly less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1 .0 g per kg of the ground product.
The content of the Beta vulgaris extracts can be substantially equal to the one of the extracts of Saccharum officinarum. It is almost equal to the one of the Medicago sativa.
The nutraceutical flour can comprise extracts of Boletus edulis suitably obtained from the whole mushroom.
The Boletus edulis extracts can comprise trimethylglicine.
The Boletus edulis extracts can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly substantially less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1 g per kg of the ground product.
The content of the Boletus edulis extracts can be substantially equal to the one of the Saccharum officinarum extracts. It is almost equal to the one of Medicago sativa and preferably of Beta vulgaris.
Preferably, the nutraceutical flour comprises extracts of Beta vulgaris and Boletus edulis. The nutraceutical flour can comprise extracts of Cynara scolymus L, in the following simply called Cynara scolymus, suitably obtained from leaves of Cynara scolymus. The Cynara scolymus extracts can comprise cynarine obtained only by a drying process.
In addition, the Cynara scolymus extracts can comprise one or more and in particular all the cynarine, polyphenols, polyacetyls, sterols, organic acids (such as 5-caffeoylquinic acid or chlorogenic acid), sesquiterpene lactones, cynaropicrin, and derivatives thereof, mineral salts, and volatile aromatic components.
The content of Cynara scolymus can be substantially less than 10.0 g, in particular less than 5.0 g, and more particularly less than 2.0 g per kg of the ground product. Preferably, it is substantially comprised between 0.05 g and 1.0 g per kg of the ground product.
The content of the Cynara scolymus can be substantially greater than the one of the Saccharum officinarum extracts. It is almost equal to the one of the Medicago sativa. The nutraceutical flour can comprise extracts of Grifola frondosa suitably obtained from the carpophore of Grifola frondosa.
The extracts of Grifola frondosa can comprise b-glucans.
The content of Grifola frondosa extracts can be substantially less than 1.0 g, in particular less than 1 .0 g, more particularly less than 0.5 g, and still more particularly less than 0.1 g per kg of the ground product. Preferably, it is substantially equal to 0.05 g per kg of the ground product.
The content of the Grifola frondosa extracts can be substantially less than the one of the Saccharum officinarum extracts.
The nutraceutical flour can comprise extracts of Cordyceps sinensis suitably obtained from the mycelium of Cordyceps sinensis. The Cordyceps sinensis extracts can comprise polysaccharides and b-glucans.
In addition, the Cordyceps sinensis extracts can comprise one or more and particularly all of cordycepic acid, galactomannan, b-mannans.
The content of the Cordyceps sinensis extracts can be substantially less than 1 .0 g, in particular less than 0.5 g, and still more particularly less than 0.1 g per kg of the ground product. Preferably, it is substantially equal to 0.05 per kg of the ground product.
The content of the Cordyceps sinensis extracts can be substantially less than the one of the Saccharum officinarum extracts. It can be almost equal to the content of Grifola frondosa extracts.
In a non-limiting example, of the formulation, the nutraceutical flour can substantially comprise a ground product and, for each kg of said ground product, from 0.4 to 0.5 g of Saccharum officinarum extracts, 1.0 g of Medicago sativa extracts, from 0.05 to 1 g of Cyclanthera pedata extracts, 1 .0 g of Silybum marianum extracts, 1.5 g of Lentinula erode extracts, 2.0 g of Avena sativa extracts, 2.0 g of Hordeum vulgare extracts, 1.0 g of Saccharomyces cerevisiae extracts, 1.0 g of Saccharomyces boulardii extracts, 1 .5 g of Berberis vulgaris extracts, 1 .0 g of Ganoderma Lucid urn extracts, 3.0 g of Vitis vinifera extracts, at least one of extracts of Beta vulgaris (content from 0.05 to 1.0 g), and Boletus edulis extracts (content from 0.05 to 1g) and, suitably, one or more of 1.0 g of Cynara scolymus extracts, 0.05 g of Grifola frondosa extracts, and 0.05 g of Cordyceps sinensis extracts.
The above described extracts can be obtained, preferably, by the Soxhlet-type reflux extraction, and in particular by ultrasounds or supercritical gases, and the addition, as solvent, of sulfur dioxide. Preferably, such extracts are obtained by the Soxhlet methanol reflux method. This method comprises: fermentation and hydrolysis of part of a plant (e.g. fruits, flowers, or leaves) from which the extracts are obtained by adding yeast suitably Saccharomycetaceae (e.g. Saccharomyces cerevisiae) and preferably with a pH of 7 for about 4 days; evaporation and centrifuging of the extracts for eliminating the solvent from the obtained solution, Soxhlet extraction; elimination of the methanol by heating it to the boiling point thereof, and consequent extraction by evaporation.
It is noted the use of other methods adapted to enable to obtain the above described extracts containing said active principles. For example, as an alternative, the Saccharum officinarum extracts can be obtained by a solvent-free cold pressing. The invention comprises a new process for producing a nutraceutical flour.
The production process can comprise a grinding step by which the ground product is obtained, for example, by grinding one or more dried fruits or plant seeds (corn, barley, emmer wheat, rice, oat, rye, chestnuts, chickpeas, almonds, and buckwheat) and similar.
The production process can comprise a step of mixing one or more of said extracts with the ground product.
In the mixing step, additional extracts of Saccharum officinarum can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Medicago sativa can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Cyclanthera pedata can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Silybum marianum can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Lentinula erode can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Avena sativa can be suitably added to the ground product in order to obtain said content.
In the mixing step, additional extracts of Hordeum vulgare can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Saccharomyces cerevisiae can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Saccharomyces boulardii can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Berberis vulgaris can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Ganoderma Lucidum can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Vitis vinifera can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Beta vulgaris can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Boletus edulis can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Cynara scolymus can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Grifola frondosa can be suitably added to the ground product according to said contents.
In the mixing step, additional extracts of Cordyceps sinensis can be suitably added to the ground product according to said contents. The production process can comprise a step of methylating at least part and in particular all the resveratrol in said extracts (suitably of Vitis vinifera) in pterostilbene.
The step of methylating folic acid (present at least in the Medicago sativa, Saccharomyces cerevisiae, and/or Saccharomyces boulardii) makes available at least part of the methyl groups present in a methyl group donor (e. g. trimethylglicine, contained in the Beta vulgaris and/or Boletus edulis extracts) which perform the step of methylating resveratrol for obtaining pterostilbene.
In this step, trimethylglicine (N,N,N-trimethylglicine or preferably a N-trimethylated amino acid in the neutral pH zwitterionic form) perform a methylating action on the resveratrol causing the formation of pterostilbene. In particular, the trimethylglicine action, by folic acid, remethylates resveratrol by reducing also 5-methyl- tetrahydrofolate (MHTF) to methyl tetrahydrofolate, which provides the methyl group required to form, by resveratrol, pterostilbene.
The nutraceutical flour according to the invention obtains important advantages. Indeed, the nutraceutical flour is effective at countering unbalances such as the ones regarding the cholesterol, immunitary and/or cardiovascular systems, hypoglycemia, due to the Vitis vinifera pterostilbene (suitably obtained by said methylation step) performing a hypocholesterolemizing, anti-inflammatory, antimicrobial, antiviral actions.
The hypocholesterolemizing action is aided by folic acid and/or Saccharum officinarum extracts which, due to policasonols, vitamins E, and B, reduce the cholesterol, in particular the LDL type. Such action is augmented by the Medicago sativa extracts which, acting on the livery and detoxification systems augment the hypocholesterolemizing action of the Saccharum officinarum and Vitis vinifera extracts.
Moreover, the addition of Cyclanthera pedata, Berberis vulgaris and/or Silybum marianum extracts increases (suitably aided by the berberine contained in Silybum marianum extracts capable of blocking the ABC transporters) the expression of the receptor for the LDLs, inhibiting their absorption in the intestine and its secretion. The hypocholesterolemizing action is increased by the Lentinula erode extracts (because they contain eritadenine) and Cynara scolymus extracts which exploit their content of cyanirine for reducing cholesterol.
Moreover, the inventor outlines the important functional contribution of the b-glucans (present in one or more of the Hordeum vulgare, Avena sativa, Lentinula erode, Cordyceps sinensis, Grifola frondosa, and/or Ganoderma Lucidum) capable of collecting and absorbing LDL cholesterol consequently contributing to the protection against cardiocirculatory diseases and strokes.
Such action is enhanced by the presence of enzyme saccharase (present in the Saccharomyces cerevisiae, Saccharomyces boulardii and/or Beta vulgaris) which, when hydrolyzed, break down saccharose into glucose and fructose.
An important action of the b-glucans is also the reduction of the hormone ghrelin and consequently the reduction of the body weight and of the visceral fat mass. This action is enhanced by extracts of Medicago sativa (capable of controlling sugars in the blood, and hyperglycemia due to the contents of alkaloids, asparagine, and trigonelline), of Berberis vulgaris and Silybum marianum (capable of increasing the hypolipemic action of berberine) and/or of Avena sativa having a fat burning action. It is noted that the b-glucans action is aided by the extracts of Saccharomyces cerevisiae and/or Sacchoromyces boulardii capable of increasing the b-glucans biosynthesis. The nutraceutical flour has strong action on the immunitary system given by the b- glucans.
Such action is synergistically enhanced by Ganoderma Lucidum which stimulates the immunitary system particularly the natural-killers and by Grifola frondosa having immunostimulant and adaptogenic actions.
Another advantage of the nutraceutical flour is its positive action on the cardiovascular system. Indeed, the policosanols of the Saccharum officinarum extracts have an anti-platelet action which consequently reduces blot clots and prevents the smooth muscle cells of the vessel wall from proliferating. To summarize, the nutraceutical flour is characterized in that it curbs and controls the hematic cholesterol levels, controls and reduces low density apolipoproteins, curbs and increases high density apolipoproteins, curbs and controls the hematic homocysteine, protects arteries and cardiocirculatory system and is characterized for its scavenging and hepatic steatosis countering actions. The invention is susceptible to be implemented in variants falling in the scope of the inventive idea defined in the claims. In such scope, all the details can be substituted by equivalent elements and materials, sizes can be of any type.

Claims

1. Nutraceutical flour comprising a ground product and characterized by comprising Saccharum officinarum, Medicago sativa, Cyclanthera pedata, Silybum marianum, Lentinula erode, Avena sativa, Hordeum vulgare, Saccharomyces cerevisiae, Saccharomyces boulardii, Berberis vulgaris, Ganoderma Lucidum, Vitis vinifera extracts and at least one of Beta vulgaris extracts and Boletus edulis extracts.
2. Nutraceutical flour according to claim 1 , wherein the content of said Medicago sativa extracts is substantially greater than the content of said Saccharum officinarum extracts; the content of said Silybum marianum extracts can be substantially equal to said content of said Medicago sativa extracts; the content of said Berberis vulgaris extracts is substantially greater than said content of said Medicago sativa extracts; the content of said Lentinula erode extracts is substantially greater than said content of said Medicago sativa extracts; the content of said Avena sativa extracts is substantially greater than said content of said Saccharum officinarum extracts and of said Medicago sativa extracts; the content of said Hordeum vulgare extracts is substantially greater than said content of said Saccharum officinarum extracts; the content of Saccharomyces cerevisiae extracts is substantially equal to said content of said Medicago sativa extracts; the content of Saccharomyces boulardii extracts is substantially equal to said content of said Medicago sativa extracts; the content of Ganoderma Lucidum extracts is substantially equal to said content of said Medicago sativa extracts; the content of Vitis vinifera extracts is greater than said content of said Medicago sativa extracts.
3. Nutraceutical flour according to at least one preceding claim, wherein said content of said Saccharum officinarum extracts is substantially comprised between
0.75 g and 0.25 g per kg of said ground product; said content of said Medicago sativa extracts is substantially comprised between 0.5 g and 2.0 g per kg of said ground product; said content of said Cyclanthera pedata extracts is substantially less than 2.0 g per kg; said content of said Silybum marianum extracts is substantially comprised between 0.5 g and 2.0 g per kg of said ground product; said content of Berberis vulgaris extracts is substantially comprised between 1.0 g and 3.0g per kg of said ground product; said content of said Lentinula erode extracts is substantially comprised between 1.0 and 3.0 g per kg of said ground product; said content of said Avena sativa extracts is substantially comprised between 1.0 g and 3.0 g per kg of said ground product; said content of said Hordeum vulgare extracts is substantially comprised between 1.0 and 3.0 g per kg of said ground product; said content of said Saccharomyces cerevisiae extracts is substantially comprised between 0.5 g and 2.0 g per kg of the ground product; said content of said Saccharomyces boulardii extracts is substantially comprised between 0.5 and 2.0 g per kg of the ground product; said content of said Ganoderma Lucidum extracts is substantially comprised between 0.5 and 2.0 g per kg of the ground product; said content of said Vitis vinifera extracts is substantially comprised between 2.5 kg and 4.0 g per kg of said ground product; and said content of said Beta vulgaris extracts or of said Boletus edulis extracts is substantially less than 2.0 g per kg of the ground product.
4. Nutraceutical flour according to at least one preceding claim, comprising Cynara scolymus extracts; and wherein the content of said Cynara scolymus extracts is substantially less than 2.0 g per kg of said ground product.
5. Nutraceutical flour according to at least one preceding claim, comprising Grifola frondosa extracts, and wherein the content of said Grifola frondosa extracts is substantially less than 0.1 g per kg of the ground product.
6. Nutraceutical flour according to at least one preceding claim, comprising Cordyceps sinensis extracts; and wherein the content of said Cordyceps sinensis extracts is substantially less than 0.1 g per kg of said ground product.
7. Nutraceutical flour according to at least one preceding claim, comprising per each kg of said ground product from 0.4 to 0.5 g of said Saccharum officinarum extracts, 1.0 g of said Medicago sativa extracts, from 0.05 g to 1.0 g of said Cyclanthera pedata extracts, 1.0 g of Silybum marianum extracts, 1.5 g of said Lentinula erode extracts, 2.0 g of said Avena sativa extracts, 2.0 g of said Hordeum vulgare extracts, 1.0 g of said Saccharomyces cerevisiae extracts, 1.0 g of said Saccharomyces boulardii extracts, 1.5 g of said Berberis vulgaris extracts, 1.0 g of said Ganoderma Lucidum extracts, 3.0 g of said Vitis vinifera extracts, and at least one of said Beta vulgaris extracts with a content between 0.05 g and 1.0 g and said Boletus edulis extracts with a content from 0.05 to 1.0 g.
8. Nutraceutical flour according to the preceding claim, comprising per each kg of said ground product 1.0 g of said Cynara scolymus extracts, 0.05 g of said Grifola frondosa extracts, and 0.05 g of said Cordyceps sinensis extracts.
9. Process for producing a nutraceutical flour comprising a step of mixing one or more of said extracts of Saccharum officinarum, Medicago sativa, Cyclanthera pedata, Silybum marianum, Lentinula erode, Avena sativa, Hordeum vulgare, Saccharomyces cerevisiae, Saccharomyces boulardii, Berberis vulgaris, Ganoderma Lucidum, Vitis vinifera and at least one of Beta vulgaris extracts and Boletus edulis extracts, with a ground product.
10. Production process according to the preceding claim comprising a methylation step wherein the folic acid in said Medicago sativa extracts make available at least some of the methyl groups present in trimethylglicine, contained in at least said Beta vulgaris extracts and/or said Boletus edulis extracts, and wherein said methyl groups methylate in pterostilbene said resveratrol contained in said Vitis vinifera extracts.
PCT/IB2020/057209 2020-07-30 2020-07-30 Nutraceutical flour WO2022023795A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/057209 WO2022023795A1 (en) 2020-07-30 2020-07-30 Nutraceutical flour

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/057209 WO2022023795A1 (en) 2020-07-30 2020-07-30 Nutraceutical flour

Publications (1)

Publication Number Publication Date
WO2022023795A1 true WO2022023795A1 (en) 2022-02-03

Family

ID=72086928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/057209 WO2022023795A1 (en) 2020-07-30 2020-07-30 Nutraceutical flour

Country Status (1)

Country Link
WO (1) WO2022023795A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105879A1 (en) * 2011-04-08 2014-04-17 Guglielmo Buonamici Flour-based functional food
US20160206670A1 (en) * 2015-01-16 2016-07-21 James A. Wieser Medicinal mycological preparations having improved potency
CN105918376A (en) * 2016-06-27 2016-09-07 吉林农业大学 Special flour for edible mushroom cake containing corn and five cereals and production method of special flour
CN107156238A (en) * 2017-06-05 2017-09-15 上海越哲食品有限公司 A kind of mushroom biscuit and preparation method thereof
CN111011836A (en) * 2019-10-11 2020-04-17 朱晋华 A functional meal-replacing food with full natural and full nutritional formula

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105879A1 (en) * 2011-04-08 2014-04-17 Guglielmo Buonamici Flour-based functional food
US20160206670A1 (en) * 2015-01-16 2016-07-21 James A. Wieser Medicinal mycological preparations having improved potency
CN105918376A (en) * 2016-06-27 2016-09-07 吉林农业大学 Special flour for edible mushroom cake containing corn and five cereals and production method of special flour
CN107156238A (en) * 2017-06-05 2017-09-15 上海越哲食品有限公司 A kind of mushroom biscuit and preparation method thereof
CN111011836A (en) * 2019-10-11 2020-04-17 朱晋华 A functional meal-replacing food with full natural and full nutritional formula

Similar Documents

Publication Publication Date Title
KR100795822B1 (en) Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tee including the same as effective components and the preparation method thereof
Tung et al. Edible mushrooms: Novel medicinal agents to combat metabolic syndrome and associated diseases
Kwon et al. A research and application of active ingredients in Bokbunja (Rubus coresnus Miuuel)
CN111689812A (en) Plant fermentation extract for improving potato planting and preparation method thereof
Naeem et al. Emerging role of edible mushrooms in food industry and its nutritional and medicinal consequences
KR102203820B1 (en) Method for producing scorched rice and scorched rice snack using grains and medicinal herb
CN101011094A (en) Waxberry tea and its preparation method
KR101710303B1 (en) Pharmaceutical composition containing elaeagnus umbellata thunberg extract for immune-enhancing
Alyahya et al. Phoenix dactylifera L.(Ajwa Dates): An energetic plant fruit with immense nutraceuticals value for strengthening the power of resistance
KR101663379B1 (en) MANUFACTURE OF FERMENTED Allium hookeri FROM YEASTS AND NATURAL ENZYME AND PREPARATION OF COMBINED BEVERAGE FOR QUENCHING THIRST
WO2022023795A1 (en) Nutraceutical flour
KR20040063680A (en) Functional vinegar containing diet enzyme, herb medicines and functional materials
CN104187629A (en) Health food with function of delaying senescence and preparation method of health food
KR100948281B1 (en) The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants
KR100986975B1 (en) Pharmaceutical composition for the treatment of atopic dermatitis
KR101402224B1 (en) Functional Foods Comprising the Extract of Gelidium elegans
KR20160149049A (en) Pharmaceutical composition for preventing or treating osteoporosis comprising an extract of black rice aleurone layer
CN101744360B (en) Antrodia camphorata extract and cigarette containing antrodia camphorata extract
CN109602721B (en) Ganoderma lucidum whole plant essence soft capsule for expelling toxin, protecting liver, improving radiation resistance and inhibiting tumor
CN107536052A (en) More plant extract formula powder of strengthen immunity bitter buckwheat and preparation method thereof
KR101772616B1 (en) Ant-stress Composition Using an Extract of Xylosma congesta
CN106937986A (en) A kind of hypoglycemic composition and preparation method thereof
KR101473748B1 (en) A Composition for Improving Obesity and Hyperlipidemia Using an Extract of Crinum asiaticum
KR101890220B1 (en) Composition for preventing, improving and treating atopic dermatitis comprising ginseng berry extract fermented using Hericium erinaceum mycelium as effective component
KR20090089487A (en) Beverage to prevent hyperglycemia, hyperpiesia and liver disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20756967

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20756967

Country of ref document: EP

Kind code of ref document: A1